__________________________________________________________****Sideways Frequency, LLC
Hello Everyone,
We had a busy week and are coming off of a high flying 20%+ mover that we profiled on Thursday. We expect that this week could be equally as busy. We are going to do something that we have not done in many years here.
We are going to take a look at a company that you aren't going to find on Robinhood or Webull. I know what you are going to say...... How does a company with over $300M in expected revenue this past year not trade on Robinhood?
The simple answer... That it is all in the works right now.
BSEM realizes that it is a 9 figure revenue producer and it is limiting it's audience be continuing to trade on the OTC.
All of the necessary forms have been filed and now it is a waiting game.
Make no mistake, once BSEM is trading on the nasdaq, an accomplishment that many set out to do but few achieve, then this one is going to get a tremendous amount of new eyes on it that were previously unaware of BSEM and their massive growth.
Take a look at the one year and three month charts below.
BSEM is definitely a mover with some a lofty $30+ price target on it.
NOTEABLE BSEM CATALYSTS:
- Working with notable clients and partners including the Center of Medicare Services (CMS), and the U.S. Department of Veterans Affairs (VA).
- Specially trained salespeople recently installed could be very effective in explaining the benefits available from using the company’s product. BSEM has added industry veterans Mirlene Guerre as Vice President of Sales and Neal Bhattcharya as Vice President of Marketing. Ms. Guerre has extensive experience leading sales teams and organizations in wound care, burn, plastics, general, and oral/ent surgical markets. Mr. Bhattacharya has held progressive positions in marketing for well-known national brands in both consumer packaged goods and medical device companies, including Kimberly-Clark, Novartis, Covidien and Trividia Health, Inc.
- The company has entered into an Agreement to acquire the majority of the assets of Auxocell Laboratories, Inc., a leading solid tissue processing equipment manufacturer. The acquisition will enable BSEM to expand its intellectual property portfolio, both domestic and foreign, in the perinatal tissue space and provide additional value to clients and shareholders.
- To date, the company has produced over 20,000 allografts, including its own Vendaje® line of products as well as contract manufacturing for many key industry players.
- BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB®”). The company’s facility is also FDA-accredited.
Biostem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
The company is providing a vital service to the human population while working to provide economic value to shareholders as well.
BSEM manufactures perinatal tissue allografts and is focused on the diabetic wound care market and the surgical wound care market.
BioStem CEO Jason Matuszewski and Chief Operating Officer Andrew Van Vurst co-founded the company in 2014. When Van Vurst’s father developed side effects from radiation treatment for cancer, resulting in partial paralysis and speech impairment, Van Vurst returned from the military to explore treatment options that would help his father regain motor function, speech and overall quality of life.
These included regenerative medicine, utilizing material derived from a human umbilical cord, that was being used to help restore tissues or organ damage because of age, disease, injury or other issues.
In 2013, Van Vurst and his father discovered South Florida-based Caribbean International Holdings, a provider of stem cell treatments.
The regenerative medicine therapy proved to be a great success for Van Vurst’s father, who regained his speech, and vastly improved his motor skills and overall quality of life. Due to the success of the treatment, Van Vurst and his father developed a passion for regenerative medicine and BioStem was born.
READ THE FULL REPORT HERE: https://www.insiderfinancial.com/profile/bsem
Sincerely,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
O22 HAS BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, LFG EQUITIES CORP FOR A ONE DAY FMST PROFILE ON 5/5/25.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.
Insider Financial
1337 Mass. AveBox 211
Arlington, MA 02476
Post a Comment
Post a Comment